UNC Lead Academic Participating Site

UNC Lineberger Comprehensive Cancer Center (UNC LCCC) seeks to continue to serve as a Lead Academic
Participating Site for the National Clinical Trials Network (NCTN). UNC LCCC is the only public NCI-designated
comprehensive cancer center in North Carolina, dedicated to improving outcomes of cancer patients across this
growing state. Ranked “Exceptional” by the NCI at the most recent review in 2015 and with $233M in cancer-
related extramural funding, UNC LCCC has an outstanding Clinical/Translational Research Program including a
centralized clinical trials office complemented by a highly engaged translational component. This Lead Academic
Participating Site (LAPS) application mirrors our clinical research program goal to improve cancer treatment by
conducting practice-changing clinical trials and fostering research that will inform the next generation of clinical
trials. UNC LCCC’s national stature in clinical research is illustrated by being one of a few centers to receive all
three competitive NCI clinical research awards in the last funding cycle (an NCTN LAPS award, a tri-center UM1
grant for participation in the Experimental Therapeutics Clinical Trials Network (ETCTN) and an NCTN Integrated
Technology Science Center (ITSC) award). As a National Clinical Trials Network (NCTN) Lead Academic
Participating Site, UNC LCCC plans to accomplish the following aims: (1) To provide scientific leadership and
intellectual input into the creation of thoughtful, feasible trials to improve the health of cancer patients; (2) To
support NCTN trials with robust accrual through our growing clinical enterprise; and (3) To provide opportunities
for excellent translational science embedded into and informing NCTN trials.

Grant Number: 3UG1CA233373-06S1
NIH Institute/Center: NIH
Principal Investigator: LISA CAREY